← All trials
NCT02212015
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2014
- Primary completion
- Dec 1, 2019
- Completion date
- Mar 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 44
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of HeidelbergLead sponsor
- University of MannheimOverall official - principal investigator
- Medical University InnsbruckCollaborator
- GlaxoSmithKlineCollaborator
- Technical University of DresdenCollaborator
- Medical University of GrazCollaborator
- University of ViennaCollaborator
- Gottfried Wilhelm Leibniz Universität HannoverCollaborator
- University of MannheimCollaborator
- University of HamburgCollaborator
- University of Duisburg-EssenCollaborator
- University of Witten/HerdeckeCollaborator
- Ludwig Maximilians UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.